NCT06596473
A Study of BG-C477 in Participants With Advanced Solid Tumors
At risk: Primary completion moved at least 6 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 36 versions: 28 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Dec 31, 2027 to Jul 23, 2028 Show 4 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 3 words
- Secondary endpoints: 13 to 16
- Study description expanded, about 156 words
- Minor Study sites: 58 to 59v35
- Minor Trial sites expanded: 54 → 58 locationsv34
- Minor Site details revised at 1 of 54 sitesv33
- Minor Study sites: 52 to 54v32
- Minor Trial sites expanded: 49 → 52 locationsv31
- Minor Trial sites expanded: 41 → 49 locationsv30
- Minor Trial sites expanded: 32 → 41 locationsv29
- Minor Trial sites expanded: 25 → 32 locationsv28
- Minor Trial sites expanded: 21 → 25 locationsv27
- Minor Study sites: 19 to 21v26
- Minor Study sites: 17 to 19v25
- Minor Study sites: 16 to 17v24
Notable Lead sponsor: BeiGene to BeOne Medicinesv23 Show 8 more changesShow less
- Enrollment target: 21 to 310
- Eligibility criteria expanded, about 75 words
- Primary endpoints revised (5)
- Study sites: 15 to 16
- Primary and study completion dates: Oct 27, 2028 to Dec 31, 2027
- Interventions: BG-C477 (Drug), Chemotherapy (Drug) to BG-C477 (Drug), Chemotherapy (Drug), Tislelizumab (Drug)
- Secondary endpoints: details revised at 8 of 13 entries
- Study description expanded, about 36 words
- Minor Study sites: 14 to 15v22
- Minor Study sites: 12 to 14v21
- Minor Study sites: 21 to 12v20
- Minor Study sites: 16 to 21v19
- Minor Study sites: 13 to 16v17
- Minor Site details revised at 4 of 13 sitesv10
- Minor Site details revised at 1 of 13 sitesv9
- Minor Site details revised at 3 of 13 sitesv8
- Minor Site details revised at 1 of 13 sitesv7
- Minor Site details revised at 1 of 13 sitesv5
- Minor Study sites: 3 to 13v4
- Minor Study sites: 1 to 3v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Oct 7, 2024 to Oct 3, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
Sequential cohorts of increasing dose levels of BG-C477 will be evaluated as monotherapy.
Selected dose levels of BG-C477 determined to be safe in Phase 1a dose escalation will be further evaluated in monotherapy.
Participants with selected advanced solid tumors will receive BG-C477 at the recommended doses for expansion (RDFEs) identified in Phase 1a.
Participants with selected advanced solid tumors will receive BG-C477 at RDFEs identified in Phase 1a in combination with anticancer agents, including chemotherapy or tislelizumab.
Drugs: BG-C477, Tislelizumab, Chemotherapy
Sites
59 sites in 8 countries
China 26, United States 10, Australia 6, Malaysia 5, Japan 4, South Korea 4, Thailand 3, New Zealand 1